T he phosphatidylinositol 3-kinase (PI3K) subfamily is divided into three classes (I, II and III) based on their structural characteristics and substrate specificity. (1, 2) Of these, the most commonly studied are the class I enzymes, which are activated directly by cell surface receptors and are associated with tumorigenesis. There are four members of class I, designed p110a, p110b, p110c and p110d. (3) The different class I isoforms have nonredundant roles and different expression profiles in different cell types. (4) (5) (6) The p110a and p110b isoforms are ubiquitously expressed, whereas the expression of p110c, which has a particular role in T-cell activation, is largely restricted to hematopoietic cells, where it is critically involved in B-cell homeostasis and function. (7) PI3Kd and its downstream target, AKT, are reported to be frequently activated in leukemic blasts from patients with B-cell malignancies or acute myeloid leukemia (AML). (8, 9) Constitutive activation of the PI3K/AKT pathway in malignant leukocytes results in sustained proliferation and survival of tumor cells. (10) Therefore, the development of selective inhibitors of PI3Kd with a high therapeutic index offers a new approach for treating hematological malignancies. Over the past 10 years, the development of PI3Kd inhibitors has made great leaps forward. (11) Currently, there are several PI3Kd inhibitors at different stages of clinical development, including AMG319, GSK226955 and INCB040093. (12, 13) Idelalisib (GS-1101, CAL-101), a more potent derivative of the highly p110d-selective inhibitor, IC87114, was approved recently to treat patients with relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic lymphoma, another type of non-Hodgkin lymphoma. (14) Acute myeloid leukemia is the most common acute leukemia in adults and is among the most lethal. There have been significant research efforts aimed at improving outcomes in AML, but the standard therapy for most subtypes of newly diagnosed AML has remained unchanged for the past four decades, and developing new therapies for AML has been challenging. (15) Thus, there remains a clear need for newer therapies and a more individualized approach for the treatment of AML. P110d, the only class I PI3K isoform consistently expressed in AML blast cells, is the main contributor to PI3K activity in AML blasts. (16) Although IC87114 inhibited AML cell proliferation, it showed weaker inhibitory activity towards p110d in AML cells compared with B-cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia cells. (14) Puquitinib, a novel selective PI3Kd inhibitor, exhibited notable safety, tolerability and efficacy against hematological malignancies in phase I clinical trials, and is currently undergoing phase II clinical trials in China. In the present study, we characterized the biochemical and cellular properties of puquitinib, and investigated its potency and selectivity for inhibition of the PI3Kd pathway. Puquitinib alone or in combination with cytotoxic agents showed superior antitumor efficacy against AML compared with CAL-101, both in vitro and in vivo. Thus, these studies provide a rationale for the clinical development of puquitinib as a PI3Kd inhibitor for treating AML.
Materials and Methods
Materials. Puquitinib and CAL-101, provided by Zhejiang Medicine (Zhejiang, China), were prepared as 50-mM stock solutions in dimethylsulfoxide for in vitro studies or normal saline in vivo studies. Lysophosphatidic acid (LPA), C5a, antiIgM, LY294002 and wortmannin were purchased from SigmaAldrich (St. Louis, MO, USA).
The appropriate primary antibodies to p110a, p110b, p110c, AKT, p-S6 235/6 , S6, p-P70S6K T389 , P70S6K, p-AKT S473 , p-AKT T308 and p-ERK1/2 were purchased from Cell Signaling (Beverly, MA, USA). Antibodies specific for p110d and ERK1/2 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell culture. RAW264.7, Raji, SK-BR-3, PC-3, MM.1R (multiple myeloma), human AML MV4;11, RS4;11, TF-1, Kasumi-1, U-937, THP-1 and KG-1a cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). Set-2, EOL-1 and Molm-16 human AML cell lines were purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen (GmbH, Braunschweig, Germany). Mo7e AML cell line was provided by the Genetics Institute (Boston, MA, USA). All cell lines were maintained in RPMI-1640 medium supplemented with 10% FBS at 37°C in a humidified 5% CO 2 atmosphere.
Cell proliferation assay. Cell proliferation was evaluated by MTT assay. (17) Briefly, cells in 96-well plates were treated in triplicate with different concentrations of drugs and incubated at 37°C for 72 h. Cytotoxicity was assessed by measuring the conversion of MTT (Sigma-Aldrich) to a colored product. GraphPad Prism version 5 (GraphPad Software, San Diego, CA, USA) curve-fitting software was used to calculate halfmaximal inhibitory concentration (IC 50 ) values.
Cell cycle analysis. After drug treatment, cells were fixed in ice-cold 70% ethanol overnight at À20°C. Fixed cells were stained with 50 lg/mL of propidium iodide containing 50 lg/ mL of DNase-free RNase A at 37°C for 30 min. The DNA content of cells (10 000 cells/experimental group) was analyzed on a FACScan flow cytometer (BD Biosciences, San Jose, CA, USA) using ModFit LT Mac V3.0 software.
In vitro kinase profiling. In vitro kinase profile assays were analyzed using Life Technologies' SelectScreen Profiling Service (Thermo Fisher, Waltham, MA, USA). PI3K ELISA were performed using a PI3Kinase Activity/Inhibitor Assay Kit (Millipore, Bedford, MA, USA) according to the manufacturer's instructions. Briefly, recombinant class I PI3K isoforms and drugs were prepared in kinase reaction assay buffer containing phosphatidylinositol 4,5-bisphosphate and incubated in a glutathione-coated 96-well plate. The plate was then treated with biotin-phosphatidylinositol 3,4,5-trisphosphate and glycine-rich protein 1 working solution. After washing, a streptavidin-HRP (SA-HRP) working solution was added, followed by addition of the HRP substrate, tetramethylbenzidine. The absorbance of each well was then measured at 450 nm using a microplate reader.
Molecular docking. Molecular modeling calculations were based on crystallographic data for the PI3K inhibitor PIK-039 in complex with PI3Kd (PDB code 2WXF). (18) Docking studies were performed using Glide software (version 5.5). (19) The obtained docked poses were analyzed with Maestro, PyMOL and LigPlot. (20) Western blotting. Cells were collected at the end of treatment and lysed in SDS sample buffer (100 mM Tris-HCl pH 6.8, 2% SDS, 20% glycerol, 1 mM dithiothreitol). Equal amounts of whole-cell lysates were separated by SDS-PAGE and electroblotted onto polyvinylidine difluoride membranes (Millipore). Blots were probed with primary antibodies, and then incubated with the appropriate secondary antibodies (Millipore). Immunoreactive proteins were visualized using enhanced chemiluminescence reagents (Millipore).
In vivo study. Female nude mice (Balb/cA-nude, 5-6 week old) were purchased from Shanghai Laboratory Animal Center, Chinese Academy of Sciences (Shanghai, China). Human carcinoma xenografts were established by inoculating nude mice subcutaneously with 5-9 9 10 6 cells. When tumors reached a volume of 100-300 mm 3 , mice were randomly assigned to control and treatment groups. Control groups were given vehicle alone, and treatment groups received oral puquitinib or CAL-101 daily. Daunorubicin or cytarabine was administered intravenously (i.v.), and co-treatment groups also received oral puquitinib daily. Tumor volume was calculated as (length 9 width 2 )/2. Pharmacokinetic/pharmacodynamic studies were carried out as described previously. (17) Mice bearing MV4;11 tumors received a single dose of 60 mg/kg puquitinib or vehicle, and tumor tissues and blood were collected at different times postdosing. Concentrations of puquitinib in plasma and tissue were determined by HPLC/tandem mass spectrometry. Tumor samples were analyzed by western blotting. Animal experiments were conducted in accordance with the Institutional Animal Care and Use Committee guidelines of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
Data analysis. Data are presented as means AE SEM and were plotted using GraphPad Prism Version 5. An unpaired twotailed Student's t-test was used to test for significance, where indicated. Differences were considered significant at P < 0.05.
Results
Puquitinib is a potent, selective inhibitor of PI3Kd. Puquitinib (Fig. 1a ) was synthesized following a high-throughput screen of a chemical library comprising compounds likely to target class I PI3K. There are four subtypes of p110, designated p110a, p110b, p110c and p110d, corresponding to the catalytic subunit of PI3Ka, -b, -c and -d, respectively.
(3) Thus, we first examined the subtype specificity of puquitinib in a biochemical kinase assay. As shown in Table 1 , puquitinib inhibited the activities of all four purified enzymes, but with substantially different potencies, exhibiting IC 50 values of 992.8, 959.2, 89.8 and 3.3 nM for p110a, -b, -c and -d enzymes, respectively. These results indicate that puquitinib is selective for p110d relative to other PI3K class I enzymes. Furthermore, puquitinib had little or no inhibitory activity against a panel of other protein kinases at a concentration of 1000 nM (Table S1) .
We next investigated the potency of puquitinib against individual PI3K class I isoforms in cell-based assays by monitoring the phosphorylation of AKT. (21, 22) Genetic and pharmacologic approaches that specifically inactivate the p110d isoform have demonstrated its important role in B-cell signaling. (23, 24) Inhibition of p110d by puquitinib was then in the phosphorylation of the PI3Kd targets, AKT, ribosomal protein S6 (S6) and extracellular signal-regulated kinase (ERK) (Fig. 1b) . LPA and C5a stimulate G-protein coupled receptor signals via PI3Kb and PI3Kc, respectively. (25, 26) Despite the decrease in LPA-or C5a ligand-stimulated phosphorylations of AKT in PC-3 or RAW 264.7 cells by puquitinib was observed, the decrease was much weaker than that of Raji cells. No obvious inhibitory activity of p110a/AKT phosphorylation by puquitinib was observed in SK-BR-3 cells (Fig. 1b) . This pharmacological profile of puquitinib is similar to that of CAL-101 in these cell-based assays. (21, 22) Thus, these data indicate that puquitinib is a potent, selective inhibitor of PI3Kd.
To understand the mechanisms underlying the isoform selectivity of this inhibitor, we further investigated the site of puquitinib binding to PI3Kd using structural modeling. The crystal structure of a PI3Kd-PIK-39 complex generated a PI3K template structure for docking analysis. (18) The docking complex revealed that the purine group of PIK-39 forms hydrogen bonds with the hinge residues, Glu826 and Val828. In this structure, the quinazolinone moiety is sandwiched into a hydrophobic pocket composed of two parts, with Trp760 and Ile777 on one side, and Met752 and Pro758 on the other side. Puquitinib yielded an interaction pattern with the ATP-binding pocket of PI3Kd that was slightly different from that of PIK-39 or CAL-101 (Fig. 1c) . Although puquitinib was found to occupy the same specificity pocket of PI3Kd, it did not form hydrogen bonds with the hinge residues Glu826 or Val828. In contrast, the purine group of puquitinib established hydrogen bonds in the ATP-binding pocket of PI3Kd with two residues, Tyr813 and Lys779.
Puquitinib exerts cytotoxicity against acute myeloid leukemia cell lines. Given the broad importance of the p110d isoform in homeostasis, we next sought to determine its expression profile and the effect of puquitinib on proliferation in a panel of AML cell lines. As shown in Figure 2a , p110d was observed in all these tested AML cell lines and there was no correlation between the expression of p110d and the other isoforms (p110a, -b and -c). MM.1R multiple myeloma cell line was used as a negative control in this experiment which lacked p110d expression. (16) Notably, puquitinib inhibited the proliferation of these p110d-positive AML cell lines with the mean IC 50 value of 0.3 lM; in contrast, minimal cytotoxicity was noted in p110d-negative MM.1R cell line (Fig. 2a) . These results suggest that sensitivity to puquitinib is associated with constitutive p110d expression in AML.
To further analyze the mechanism of puquitinib-induced cytotoxicity, we next examined the effect of puquitinib on the cell cycle profile. Treatment with puquitinib for 24 h induced a concentration-dependent G 1 -phase cell-cycle arrest in p110d-positive MV4;11 cells. The proportion of G 1 -phase cells was increased from the control level of 63.3-83.0%, and 70.7% by 1 lM puquitinib and 1 lM CAL-101, respectively (Fig. 2b) .
Next, we measured apoptosis induced by puquitinib in MV4;11 cells. With prolonged treatment with puquitinib for 48 h, Annexin V-positive cells increased in a dose-dependent manner (Fig. S1 ). The apoptosis induction by puquitinib was further evidenced by increased levels of cleaved caspases and poly-(ADP-ribose) polymerase (PARP) both in MV4;11 and RS4;11 cells (Fig. 2c) . This apoptosis-inducing effect was significant following treatment with 1 lM puquitinib and became more pronounced at a concentration of 10 lM, while CAL-101 treatment caused weaker induction of apoptosis (Fig. 2c) .
Puquitinib inhibits constitutive PI3K signaling in acute myeloid leukemia cells. A previous study showed that inhibition of p110d by CAL-101 triggers cytotoxicity in association with inhibition of AKT and ERK phosphorylation. (27) Thus, we next examined the effect of puquitinib on these pathways in AML cell lines. As expected, puquitinib significantly inhibited phosphorylation of AKT and ERK in p110d-positive Kasumi-1 and EOL-1 AML cells, but did not affect phosphorylation of AKT or ERK in MM.1R cells with low expression of p110d (Fig. 3a) . Puquitinib also inhibited constitutive PI3K signaling in MV4;11 cells in a concentration-dependent and time-dependent fashion (Fig. 3b) . However, in this study, CAL-101 preferentially inhibited phosphorylation of AKT relative to ERK in these AML cells.
Consistent with a previous report, PI3K activity following inhibition by LY294002 rapidly recovered after removal of the drug, but did not recover following treatment with the irreversible inhibitor wortmannin (Fig. 3c) . The effects of puquitinib, similar to those of CAL-101, readily reversed following compound removal, with the levels of phosphorylated AKT (pAKT) and those of downstream factors returning to control values (Fig. 3c) . Thus, puquitinib appears to act through both PI3K/AKT and MEK/ERK pathways in these AML cells.
In vivo antitumor activity of puquitinib alone in acute leukemia xenografts. Given its encouraging activity in vitro, we next investigated the antitumor efficacy of puquitinib in vivo, initially conducting a pharmacokinetic/pharmacodynamic study in the MV4;11 tumor xenograft model. After a single oral dose of 60 mg/kg puquitinib, plasma and tumors were collected at various time points over a 24-h period. As shown in Figure 4a , puquitinib appeared rapidly in plasma and tumor tissue. The phosphorylation of AKT and ERK in tumor tissue was inhibited in a time-dependent manner from 0.5 to 24 h after compound administration (Fig. 4b) , a finding that was concordant with the changes in plasma and intratumoral concentrations of puquitinib (Fig. 4a) .
We next examined the antitumor activity of puquitinib against MV4;11 xenografts. Oral administration of puquitinib significantly inhibited the growth of MV4;11 xenografts in a dose-dependent manner (Fig. 4c) . Administration of puquitinib at a dose of 30 or 60 mg/kg inhibited tumor growth by 72 and 103%, respectively, on the final treatment day. Complete tumor regression was observed in three of six tumors at the higher dosage. This growth inhibition was superior to that produced by CAL-101, which inhibited tumor growth by 50 and 61% following oral administration of a dose of 90 or 180 mg/ kg, respectively. The in vivo antitumor activity of puquitinib was further examined in RS4;11 xenografts. Administration of 30 and 60 mg/kg puquitinib inhibited tumor growth by 50 and 69%, respectively (Fig. 4c) . These treatments were well tolerated, as evidenced by the absence of significant body weight loss or other obvious signs of toxicity during the course of the experiment in all groups. Furthermore, the in vivo antitumor activity was also well correlated with the inhibition of PI3K signaling. In both tumor models, puquitinib treatment significantly decreased the levels of pAKT and pERK in tumor tissues (Fig. 4d ).
Combined puquitinib with cytotoxic drugs mediates enhanced effects in acute myeloid leukemia. Cytotoxic drugs are widely used alone or in combination to treat leukemia. Thus, we investigated whether inhibition of p110d by puquitinib combined with the cytotoxic drugs, daunorubicin, aclarubicin or fludarabine, exerted a potentiating effect on antitumor activity. The contribution of combination treatment to cellular activity compared with the effect of the two agents alone was evaluated by calculating the combination index (CI) using Calcusyn software, where CI < 1 denotes synergy, CI = 1 indicates an additive effect and CI > 1 reflects antagonism. As shown in Table 2 , puquitinib showed synergistic effects in inhibiting the growth of MV4;11 cells when combined with each of the tested cytotoxic drugs, effects that were also confirmed in RS4;11 cells (Table 2) .
Finally, we investigated the efficacy of combined treatment with puquitinib and daunorubicin or cytarabine in MV4;11 xenografts. Consistent with the in vitro results, puquitinib, combined with either of these two drugs, produced enhanced antitumor efficacy compared with each single agent (Fig. 5a,  b) . This was especially notable for puquitinib combined with daunorubicin, which produced an antitumor efficacy that was significantly superior to that of the corresponding single agents (P < 0.01). The combination of puquitinib with daunorubicin or cytarabine was generally well tolerated without additional observed toxicity (Fig. 5a,b) . tumor-bearing mice were orally administered a single 60-mg/kg dose of puquitinib and killed at the indicated times. The concentration of puquitinib in blood plasma and tumor tissues was determined (a). In parallel, tumor extracts were analyzed by western blotting (b). (c) MV4;11 and RS4;11 tumor-bearing mice were orally administered vehicle (n = 12) or puquitinib (n = 6) daily for 21 days at the indicated doses. Tumor volumes were measured. *P < 0.05, **P < 0.01 versus vehicle. (d) Mice were killed 3 h after the last dose, then tumors were removed and analyzed by western blotting.
Discussion
The PI3Kd isoform is the most important isoform in hematologic cells and has been implicated as a potential target for the treatment of hematological malignancies. (28) Recently, several new PI3Kd isoform-selective inhibitors showing improved selectivity and potency have been reported. (12, 13) In the current study, puquitinib was characterized as a novel PI3Kd inhibitor, and was shown to significantly and selectively inhibit PI3Kd activity, notably outperforming CAL-101 both in vitro and in vivo against AML. This promising pharmaceutical activity may support the potential clinical use of puquitinib for the treatment of AML.
A previous study suggested that almost all selective inhibitors create a new specificity pocket in the enzyme that can be exploited to augment their potency towards PI3Kd. (18, 29) Our docking result revealed that puquitinib bound persistently to PI3Kd, and interacted with the specificity pocket and affinity pocket in the active site of PI3Kd. The purine group of puquitinib established two hydrogen bonds in the ATP-binding pocket of PI3Kd (one with Tyr813 and one with Lys779) instead of forming hydrogen bonds with Glu826 and Val828, as is the case for CAL-101. (29) This suggests that the specific pattern of hydrogen bonding accounts for the potency and selectivity of puquitinib for PI3Kd kinase compared with other protein kinases. Indeed, the PI3Kd inhibitory activity of puquitinib, with an IC 50 value of 3.3 nM, was comparable to that of CAL-101. Puquitinib was also 27-300-fold more potent against PI3Kd than other class I PI3K isoforms, and was highly selective when profiled against other protein kinases. Furthermore, the PI3Kd-isoform selectivity of puquitinib translated well to cell-based assays, in which puquitinib inhibited p110d-dependent responses at low nanomolar concentrations.
The p110d isoform is highly expressed in cells of hematopoietic origin, and has important roles in promoting proliferation and survival. (8) A total of 11 AML cell lines were randomly chosen for direct evaluation of the cytotoxicity of puquitinib in vitro. Puquitinib showed cytotoxicity against all tested p110d-positive AML cell lines with the mean IC 50 value of 0.3 lM, indicating that puquitinib is more potent than CAL-101. In contrast, puquitinib was minimally cytotoxic towards p110d-negative cancer cell lines, and showed no cytotoxicity against peripheral blood mononuclear cells even at a concentration of 10 lM (data not shown). Of these cell lines, Flt3-ITD MV4;11 was the most sensitive to puquitinib, with an IC 50 value of 0.1 lM; by comparison, the IC 50 value for CAL-101 in this cell line was 2.4 lM (data not shown). Additional studies showed that puquitinib exerted greater cell-cycle arrest and apoptosis effects than CAL-101 in MV4;11 cells. These results suggest that sensitivity to puquitinib is associated with constitutive p110d expression and imply a favorable therapeutic window.
Acute myeloid leukemia is associated with poor long-term survival. The development of new therapeutic strategies against specific targets is an area of intense interest, and such approaches may prove effective as adjunct treatments in combination with traditional chemotherapy. (15) P110d is consistently expressed at high levels in AML blast cells, and is the main contributor to PI3K activity in AML blasts. (8) Oral administration of puquitinib alone inhibited the growth of MV4;11 xenografts in a dose-dependent manner and caused complete regression of three of six tumors at a dose of 60 mg/ kg. Cytotoxic drugs, such as VP16, daunorubicin and aclarubicin, are widely used, alone or in combination, for the treatment of AML. (30) Outside a clinical trial setting, most patients with newly diagnosed AML are offered the combination of standard-dose cytarabine together with an anthracycline (daunorubicin or idarubicin). (31) In the current study, puquitinib combined with these cytotoxic drugs, especially daunorubicin, produced a greater effect than treatment with each agent alone, without producing added toxicity. Thus, puquitinib was well tolerated, caused disease stasis when administered orally, and enhanced efficacy when used in combination with conventional chemotherapeutic agents, suggesting that puquitinib is a good alternative option for the treatment of AML in the clinic.
It has been reported that PI3Kd and its downstream target, AKT, are frequently activated in leukemic blasts from patients with B cell malignancies or AML. (32) (33) (34) In the present study, PI3K/AKT and ERK signaling were selectively inhibited by puquitinib in p110d-positive AML cells, but not in p110d-negative MM.1R cells, which was demonstrated in anti-IgMstimulated Raji cells, suggesting that puquitinib inhibited EKR activation in a p110d-dependent manner. Although ERK is not a classical downstream target of PI3K signaling, sporadic studies have reported that the inhibition PI3Kd inhibition might lead to inactivation of ERK. (21, 22) It has been reported that CAL-101 blocks ERK phosphorylation in myeloma and chronic lymphocytic leukemia cells, (27, 35) which is consistent with our results in anti-IgM-stimulated Raji cells. Interestingly, despite the overexpression of PI3Kd in AML, CAL-101 does not significantly inhibit ERK signaling. In contrast, puquitinib significantly inhibits ERK activation in AML, suggesting that these two drugs may bear different pharmacological profiles besides the PI3Kd in AML, which may result in puquitinib's superior antitumor activity. PI3K signaling disrupts insulin signaling, and hyperglycemia has been considered a toxic side effect of PI3K inhibition; (36, 37) however, a previous study revealed no puquitinib-related hyperglycemia. (38) Thus, the specific targeted inhibition of PI3Kd by puquitinib preserved PI3K signaling in normal and non-neoplastic cells, which may result in minimal toxicity.
Taken together, the results of our study demonstrate that puquitinib, a novel orally available PI3Kd inhibitor, has significant antitumor activity against AML both in vitro and in vivo, with evidence of target modulation, and this activity is enhanced when combined with cytotoxic agents. Given that puquitinib exhibits reduced nephrotoxicity and superior antitumor activity in AML, puquitinib, as well as puquitinib-based regimens, likely warrant further clinical investigation for the treatment of AML.
